Ranolazine Cardioprotection in PCI

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2013 by Kettering Health Network.
Recruitment status was  Recruiting
Gilead Sciences
Information provided by (Responsible Party):
Harvey Hahn, Kettering Health Network
ClinicalTrials.gov Identifier:
First received: November 28, 2012
Last updated: May 2, 2013
Last verified: May 2013

November 28, 2012
May 2, 2013
November 2012
November 2013   (final data collection date for primary outcome measure)
  • Troponin [ Time Frame: 8-10 hrs post PCI ] [ Designated as safety issue: No ]
    Troponin labs will be drawn 8-10 hrs after PCI or at discharge whichever comes first
  • CK-MB [ Time Frame: 8-10 hrs post PCI ] [ Designated as safety issue: No ]
    CK-MB labs will be drawn 8-10 hrs after PCI or at discharge whichever comes first
Same as current
Complete list of historical versions of study NCT01767987 on ClinicalTrials.gov Archive Site
  • TIMI flow rates [ Time Frame: During the PCI ] [ Designated as safety issue: No ]
  • Incidence of atrial fibrillation, ventricular tachycardia, or ventricular fibrillation in coronary cath lab [ Time Frame: During the PCI ] [ Designated as safety issue: Yes ]
  • Incidence of non-sustained ventricular tachycardia or atrial fibrillation post PCI [ Time Frame: Following completion of PCI through hospital discharge ] [ Designated as safety issue: Yes ]
  • Left ventricular end diastolic pressure (LVEDP) [ Time Frame: During the PCI ] [ Designated as safety issue: No ]
  • Successful PCI, death, myocardial infarction (biomarker greater than 2x normal), CHF, cardiac arrest [ Time Frame: At discharge or within 1 days, whichever comes first ] [ Designated as safety issue: Yes ]
  • Death, MI, Revascularization, CHF [ Time Frame: 1-4 weeks post PCI ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
Ranolazine Cardioprotection in PCI
Ranolazine Cardioprotection in PCI

The investigators will test if upfront dosing of Ranolazine can reduce myocardial biomarker release (CK-MB, Troponin) post percutaneous coronary intervention (PCI).

Ranolazine has been demonstrated to decrease angina, ischemia on perfusion imaging, improve diastolic function, and cardiac metabolism. Furthermore it has been associated with reduced cardiac arrhythmias, including non-sustained ventricular tachycardia and atrial fibrillation. It has not been studied as an acute cardioprotective agent in percutaneous coronary intervention (PCI).

We hypothesize that upfront administration of Ranolazine could decrease the myocardial injury associated with PCI due to all the factors listed above (i.e. precondition the myocardium). We plan to screen all patients scheduled for an elective coronary angiogram. Those who meet criteria and consent will be randomized to either receive Ranolazine or placebo twice a day for 3 days leading up to the PCI.

Phase 2
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
Acute Coronary Syndrome
  • Drug: Ranolazine
    Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI
    Other Name: Ranexa
  • Drug: Placebo
    Drug: Placebo Oral dose twice per day for 3 days leading up to PCI
  • Active Comparator: Ranolazine
    Oral treatment Intervention: Drug: Ranolazine 1000 mg
    Intervention: Drug: Ranolazine
  • Placebo Comparator: Placebo
    Oral treatment Intervention: Drug: Placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Not Provided
November 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age 18 or older
  • Patients undergoing Coronary Angiography with possible PCI
  • Able and willing to give consent
  • Able to read and write English

Exclusion Criteria:

  • Current EKG or Biomarker of Acute Myocardial Infarction (MI) or Acute Coronary Syndromes (ACS)
  • History of Allergy to Ranolazine
  • Pregnant or Nursing
  • Currently taking Ranolazine
18 Years and older
Contact: Harvey S Hahn, MD 937-312-9890 harvey.hahn@khnetwork.org
Contact: Brandi L Palmer, MS 937-395-8227 brandi.palmer@khnetwork.org
United States
ISR IN-US-259-0139
Harvey Hahn, Kettering Health Network
Harvey Hahn
Gilead Sciences
Principal Investigator: Harvey S Hahn, MD Kettering Health Network
Kettering Health Network
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP